- posted in News Release
Toronto, ON, Canada September 28, 2011 – Bio Pharma Services Inc. (BPSI) announced that Mr. Renzo DiCarlo has been promoted to Chief Executive Officer effective immediately. Mr. DiCarlo joined BioPharma in February 2011 as Chief Operating Officer.
Previous to BioPharma, Mr. DiCarlo had senior management posts at SNC-Lavalin in Toronto, Canada, and at MDS’ Global Central Laboratory Business in Toronto, Canada, Nordion SA Business in Charleroi, Belgium and Nuclear Medicine Business in Ottawa, Canada.
He leads BioPharma Services Inc. as it celebrates its fifth-year of service, with more than 120 staff members and an established and US FDA-inspected, UK-MHRA inspected, and Health Canada-inspected 158-bed Phase I/IIa and BE study clinical facility in Toronto, Canada, and the planned opening of a new bioanalytical laboratory in Toronto, Canada in October.
“As BioPharma Services’ new CEO, I am proud and humbled to be working for and with our employees, and our clients who are focused on drug development and research. We are a company that values its people, makes a difference in society and expedites medical research. I am thrilled to be working with the executive team and the Board in continuing to grow BPSI as an early stage drug development success story,” commented Mr. DiCarlo regarding his new role.
Dr. Esmat Dessouki steps down as CEO, but he remains Board Member and Principal Investigator of BioPharma Services Inc.
About BioPharma Services Inc.
BioPharma Services Inc. is a physician-owned, physician-run, FDA-inspected, UK MHRA-inspected, and Health Canada-inspected Canadian Contract Research Organization (CRO) which specializes in the conduct of Bioequivalence (BE) Studies for generic pharmaceutical companies, and Phase I/IIa clinical trials for innovative pharmaceutical companies from US, Canada, Australia and Europe. The company currently has a modern 158-bed clinical facility based in Toronto, Canada. It is privately held, and it is headquartered in Toronto, Canada.
For more information regarding this release, please contact Ms. Lorelei Lutter at llutter[at]biopharmaservices.ca